Skip to main content
. 2023 Aug 14;16:2223–2227. doi: 10.2147/CCID.S424310

Figure 1.

Figure 1

Skin lesion performance of abrocitinib before and after treatment of patients with EPPP. (a) Skin lesions prior to the treatment; (b) Lesion at higher magnification; (c) Significant improvement in the degree of skin lesions after one month of treatment with abrocitinib.